Sanofi

Press Release: Statement on FTC challenge to proposed license agreement with Maze Therapeutics

Retrieved on: 
Monday, December 11, 2023
Heart, Maze, Patient, Hope, Sanofi, Partnership, Knowledge, FTC, Therapy, Pharmaceutical industry

Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.

Key Points: 
  • Sanofi is disappointed with the Federal Trade Commission’s announcement that it is seeking a preliminary injunction against a proposed licensing agreement between Sanofi and Maze Therapeutics.
  • We respectfully disagree with the action by the FTC which also delays potential advancements that could impact the lives of patients.
  • The Maze partnership was designed to apply Sanofi’s resources, knowledge, and expertise to accelerate the development of MZE001, with the hope of addressing unmet medical needs for this devastating condition.
  • Sanofi remains committed to address the Pompe patient community’s unmet needs.

Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi

Retrieved on: 
Thursday, December 7, 2023
Sanofi, HS, Inflammation, Disease, Doctor of Philosophy, Therapy, Oral medicine, International development, TPD, Patient, Safety, Pharmaceutical industry

WATERTOWN, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of small molecule medicines using targeted protein degradation (TPD), today announced that the first patient has been dosed in the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in AD, generating a $15 million milestone payment under its collaboration with Sanofi. The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD. Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023, which generated a $40 million milestone payment under the terms of the collaboration. Study completion dates for both trials are projected in the first quarter of 2025.

Key Points: 
  • The Phase 2 study will evaluate the efficacy and safety of KT-474, a first-in-class, investigational IRAK4 degrader, compared with placebo in adult patients with moderate to severe AD.
  • Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023 , which generated a $40 million milestone payment under the terms of the collaboration.
  • Study completion dates for both trials are projected in the first quarter of 2025.
  • “We are pleased to be working with Kymera to explore the potential of IRAK4 degradation to treat a variety of inflammatory conditions, including in our recently initiated Phase 2 AD and HS trials.”

IGM Biosciences Announces Strategic Pipeline Prioritization and Cash Runway Extension

Retrieved on: 
Tuesday, December 5, 2023
Workforce, DR5, Sanofi, IND, Antibody, FDA, Colorectal cancer, FOLFIRI, CD20, SLE, IGM, Clinical trial, Rheumatoid arthritis, Inflammation, Investigational New Drug, Lupus, CD38, Bevacizumab, Myopathy, Myositis, Patient, Immunoglobulin M, Vaccine

In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.

Key Points: 
  • In conjunction with this strategic refocusing, the Company will be reducing its workforce by approximately 22 percent.
  • As a result of these actions, IGM expects to extend its cash runway into the second quarter of 2026.
  • “IGM continues to have a tremendous opportunity to transform a variety of disease areas using an entirely new class of antibody medicines,” said Fred Schwarzer, Chief Executive Officer of IGM Biosciences.
  • As a part of this strategic refocusing, the Company will halt the following clinical development activities:

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Retrieved on: 
Monday, December 4, 2023
Phase, Immune system, Infection, AstraZeneca, Executive Committee, Doctor of Philosophy, Novartis, Neoplasm, Celgene, M.D, Hematology, Patient, Bristol Myers Squibb, Sanofi, Bone marrow, Vaccine

Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise

Key Points: 
  • Smart Immune appoints Dr. Rahim Fandi, M.D, PhD as Chief Medical Officer, strengthening C suite with seasoned oncology expertise
    PARIS, France, 04 December 2023 – Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T cell progenitor therapy platform to fully and rapidly re-arm the immune system against tumors and infection, today announces the appointment of Dr. Abderrahim (Rahim) Fandi as Chief Medical Officer, effective immediately.
  • Dr Fandi brings more than 25 years of experience of oncology clinical development programs in the pharmaceutical and biotechnology industry.
  • Prior to this, Rahim held senior clinical research and development positions at Celgene, Novartis, Bristol Myers Squibb and AstraZeneca.
  • Karine Rossignol, Chief Executive Officer of Smart Immune, said: “Rahim’s extensive experience in clinical development to explore new immuno-oncology technologies will be an invaluable asset to Smart Immune.

20Med Therapeutics Appoints Industry Veteran Hugo Fry as Chief Business Officer to Expedite mRNA Vaccine Delivery Platform Program

Retrieved on: 
Wednesday, November 29, 2023
Commercialization, LNP, Sanofi, London Business School, Drug discovery, Messenger, Nuclear power plant, CEPI, JPMorgan Chase, Therapy, Duke University, University, Market access, TouchLight, Regulatory affairs, PNP, Publication, Infection, Vaccine

Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.

Key Points: 
  • Leiden, The Netherlands, November 29, 2023 – 20Med Therapeutics, a leader in non-viral delivery of mRNA vaccines, today announced the appointment of Hugo Fry as Chief Business Officer.
  • Hugo Fry has 29 years of leadership experience in the pharmaceutical and biotechnology industry across multiple business models, therapeutic areas, and companies, including Sanofi.
  • Hugo has a strong and recent track record of business development and licensing deals in the pharma and biotech sectors.
  • +++ Meet the 20Med Therapeutics team in San Francisco during the JPMorgan week, January 8-12, 2024 to discuss partnering opportunities around our PNP mRNA vaccine delivery platform +++

Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease

Retrieved on: 
Monday, November 27, 2023
Patient, Regeneron Pharmaceuticals, Sanofi, Food, Smoker, Death, Aes, Breakthrough therapy, Upper respiratory tract infection, Diarrhea, FDA, Hypertension, Headache, Disease, Common, Inflammation, COVID-19, European Medicines Agency, Back pain, Phenotype, Safety, History, Pharmaceutical industry

The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.

Key Points: 
  • The second Dupixent® (dupilumab) investigational Phase 3 chronic obstructive pulmonary disease (COPD) trial (NOTUS) has shown that Dupixent significantly reduced (34%) exacerbations, confirming positive published results from the landmark Phase 3 BOREAS trial.
  • These results were from an interim analysis and, given the overwhelming positive efficacy of the primary endpoint, will be considered the primary analysis of the trial.
  • Patients receiving Dupixent compared to placebo experienced:
    34% reduction in moderate or severe acute COPD exacerbations over 52 weeks (p=0.0002), the primary endpoint.
  • The safety and efficacy of Dupixent in COPD are currently under clinical investigation and have not been evaluated by any regulatory authority.

Exscientia Announces Expansion of its Current Collaboration with Sanofi to Include Existing Exscientia Programme

Retrieved on: 
Thursday, December 21, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Artificial Intelligence, Technology, Growth, Sanofi, Pharmaceutical industry

Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration.

Key Points: 
  • Exscientia plc (Nasdaq: EXAI) today announced that Sanofi is adding a new discovery stage programme identified and initially advanced by Exscientia into the current collaboration.
  • In this programme, Exscientia has designed a novel lead series with a potential best in class profile, with preliminary data showing good potency and selectivity towards the target and differentiated molecular properties.
  • “Sanofi adding an Exscientia discovery stage programme into the collaboration speaks to the strengths of our AI-driven platform to solve complex drug discovery problems,” said Professor Andrew Hopkins FRS FMedSci, founder and Chief Executive Officer of Exscientia.
  • “The growth of our collaboration is a testament to our strong relationship with Sanofi and our shared vision for AI-enabled drug discovery.

Global Times: Path to modernity: 45 years on, continuous reform and opening-up underpins pursuit of Chinese modernization

Retrieved on: 
Wednesday, December 20, 2023
Conference, Global Times, Hoxhaism, Sanofi, Communist party, Central committee, Shoe, International Fair, Knowledge, CPC, The Lego Group, Clothing, Growth, Investment, McDonald's, Airbus, Central Economic Work Conference, Real-time, Environment

Yet, this particular place provides a vintage point to view unprecedented changes China's 45 years of reform and opening-up brought to Shenzhen, the country as well as the world.

Key Points: 
  • Yet, this particular place provides a vintage point to view unprecedented changes China's 45 years of reform and opening-up brought to Shenzhen, the country as well as the world.
  • All of these are snapshots depicting the miraculous achievements of China's reform and opening-up over the past 45 years, its rising global significance, as well as the clear path forward as China is in full swing to pursue Chinese modernization.
  • "Chinese modernization is the result of reform and opening-up, which was true in the past, still is at present and will be in the future."
  • China's commitment to deepening reforms and expanding high-level opening-up offers great boost for global businesses' confidence in China.

C4 Therapeutics Strengthens Board of Directors with Owen Hughes Appointment

Retrieved on: 
Monday, November 20, 2023
Research, Therapy, Dartmouth College, Disease, History, Patient, Investment, Bain Capital, C4, Fidelity Investments, Sanofi–Translate Bio COVID-19 vaccine, Physician, Intarcia Therapeutics, CCCC, Management, Sanofi

WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.

Key Points: 
  • WATERTOWN, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced the appointment of Owen Hughes to its board of directors.
  • Mr. Hughes is an accomplished life sciences executive with nearly three decades of experience in investing, operations and corporate governance.
  • “We are thrilled to welcome Owen to the board of directors and leverage his experience across capital markets and pivotal business development opportunities,” said Bruce Downey, chairman of the board of directors of C4 Therapeutics.
  • “I look forward to working with the board of directors and management team to capitalize on the company’s scientific prowess to the benefit of patients and shareholders alike.”

T-Therapeutics raises £48 million Series A for development of next generation TCR therapeutics to transform cancer treatment

Retrieved on: 
Wednesday, November 15, 2023
University, TCR, Logic, Tissue, CIC, Biotechnology, Sanofi, Digitalis, Patient, Inflammation, Sofinnova, GSK, Neoplasm, Therapy, Cancer, Human, Immunotherapy, Pharmaceutical industry, Vaccine

The proceeds will be used to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.

Key Points: 
  • The proceeds will be used to discover and develop novel T cell receptor (TCR) therapeutics for cancer indications as well as inflammatory disorders.
  • Concurrent with the financing, Graziano Seghezzi (Sofinnova Partners), Nihal Sinha (F-Prime), Samuel Bjork (Digitalis) and Robert Tansley (CIC) will join the Company’s Board of Directors.
  • Initially, these treatments are being designed to recognise specific cancers and recruit the patient’s own T cells to eradicate the tumour.
  • We are proud to be alongside Allan and the team as they pioneer a new era in cancer treatment.”